Table 1 Data Collection Schedule
Period | Screening | Treatment period | Followup | |||
|---|---|---|---|---|---|---|
Visit | 1st (D -7) | 2nd (D 1) | 3rd (D 15) | 4th (D 29) | 5th (D 57) | (D 71) |
Informed consent | â—¯ | |||||
Demographic characteristics | â—¯ | |||||
Medical History | â—¯ | |||||
Safety Assessment | â—¯ | â—¯ | â—¯ | â—¯ | â—¯ | |
Total IgE, Eosinophil count | â—¯ | â—¯ | â—¯ | |||
SCORAD Index | â—¯ | â—¯ | â—¯ | â—¯ | ||
Dermatology Life Quality Index | â—¯ | â—¯ | ||||
EQ-5D | â—¯ | â—¯ | ||||
Health Utilities Index Mark 3 | â—¯ | â—¯ | ||||
Adverse effects | â—¯ | â—¯ | â—¯ | â—¯ | ||
Blinding Assessment | â—¯ | |||||